XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
  Hypertension
  CAD
  Myocardial Infarction
  CHF
  Clinical Trials
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

The CHARISMA trial

Clinical Trials Channel
subscribe to Clinical Trials newsletter

Latest Research : Cardiology : Clinical Trials

   DISCUSS   |   EMAIL   |   PRINT
Clopidogrel and aspirin combination fails to show long term beneficial affects in stable vascular patients
Mar 18, 2006 - 2:17:00 AM, Reviewed by: Dr. Rashmi Yadav

�Patients taking Clopidogrel (Plavix�) should not stop taking the anti-clotting drug without first consulting their physician."

 
While the CHARISMA trial (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance) results have shown no benefit overall of the combination of Clopidogrel and aspirin in the long term in stable vascular patients, and some indication of harm in patients in primary prevention, the ESC would like to remind patients that dual antiplatelet therapy is an essential, approved and recommended therapy for one year in patients post ACS without ST-segment elevation, and for at least six months post stenting.

�Patients taking Clopidogrel (Plavix�) should not stop taking the anti-clotting drug without first consulting their physician,� said ESC spokesperson on Acute Coronary Syndromes, Professor Freek Verheugt from Radboud University Medical Center, Nijmegen, Netherlands. �Patients who stop taking Clopidogrel without seeking the advice of their doctor may be putting themselves in grave danger.�

For more information, please see current ESC guidelines for �Percutaneous Coronary Intervention� (1) (http://www.escardio.org/knowledge/guidelines/PCI-Guidelines.htm) and �Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation� (2) (http://www.escardio.org/knowledge/guidelines/Management_ACS_without_persistent_ST-segment_elevation.htm).

The CHARISMA trial was presented at the Annual Scientific Sessions of the American College of Cardiology in March 2006 and simultaneously published on the website of The New England Journal of Medicine (http://content.nejm.org/).

The European Society of Cardiology (ESC)

The ESC represents more than 45,000 cardiology professionals across Europe and the Mediterranean. Its mission is to improve the quality of life of the European population by reducing the impact of cardiovascular disease.

The ESC achieves this through a variety of scientific and educational activities including the coordination of: clinical practice guidelines, education courses and initiatives, pan-European surveys on specific disease areas and the ESC Annual Congress, the largest medical meeting in Europe. Furthermore, the ESC promotes cardiovascular disease prevention messages to the general public, most notably during its annual 'For Your Heart's Sake' event, a fun yet educational event offering risk assessment and prevention advice, held in parallel to the Congress each year.

 

- The CHARISMA trial was presented at the Annual Scientific Sessions of the American College of Cardiology in March 2006 and simultaneously published on the website of The New England Journal of Medicine
 

http://www.escardio.org/

 
Subscribe to Clinical Trials Newsletter
E-mail Address:

 

Reference:
(1) European Heart Journal 23, 1809�1840: 2002; Michel E. Bertrand, Chair, Maarten L. Simoons, Keith A. A. Fox, Lars C. Wallentin, Christian W. Hamm, Eugene McFadden, Pim J. De Feyter, Giuseppe Specchia, Witold Ruzyllo, �Acute Coronary Syndromes in Patients Presenting without persistente ST-segment elevation (Management of).�

(2) European Heart Journal 26, 804-847: 2005; S. Silber (Chairperson), P. Albertsson, F. Fernandez-Avil�s, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J-E. Nordrehaug, W. Ruzyllo, P. Urban, G. W. Stone, W. Wijns, �Percutaneous Coronary Interventions (Guidelines for).�


Related Clinical Trials News

Pre hypertension best managed by early pharmacological intervention
Patients should not discontinue clopidogrel without consultation
Clopidogrel and aspirin combination fails to show long term beneficial affects in stable vascular patients
Bluhm Cardiovascular Institute Surgeons Implant Heart Pump in Comparative Study of Two Devices
Ground-breaking heart stem cell trial (REGENERATE) now underway


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us